Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Keep out of the reach of young children
50% of Mochi patients lose at least 10% of their body weight within six months
Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes, offering substantial HbA1c reductions of 1.9% to 2.6%
Therefore, maintaining the balance between A1 and A2 astrocytes to suppress neuroinflammation is a crucial strategy for treating PND
12.15.25 New MDL formed for NAION cases The U.S
US$ 25.80
US$ 20.36
US$ 29.72
US$ 25.98
US$ 22.11
US$ 22.42
US$ 20.04
US$ 20.46
US$ 24.21
